Study of AMDX-2011P for primary open angle glaucoma
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests an investigational drug called AMDX-2011P for people with primary open angle glaucoma in both eyes. It aims to see if the drug can help protect the optic nerve and preserve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary open angle glaucoma in both eyes.
- You are able to focus your gaze and keep it steady (fixate).
- Your doctor has confirmed that glaucoma has damaged your optic nerve in both eyes.
- You can read and write.
- You do not have any other eye diseases besides glaucoma (cataracts are okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an eye drop (G01) for people with primary open-angle glaucoma that is getting worse despite current treatments. It aims to see if G01 can safely slow down or stop the progression of glaucoma.
This trial tests an investigational drug called AMDX-2011P for people with Alzheimer's disease. It looks at whether the drug affects the retina, which may be linked to brain changes in Alzheimer's.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
Hear when a new Primary Open Angle Glaucoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.